Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term. Here you will gain full access to all profitable insight available from our team of analysts. Learn more about Zacks Equity Research.
The company filed the NDA for its lead drug Feraheme in December 2007, and the drug was approved by the FDA on June 30, 2009. Clinical data in over 1,700 patients indicate an excellent safety profile for the drug with lower incidents of heart problems.
Clinical results and eventual approval for additional indications should ensure strong growth in the coming years. We maintain our Buy rating on the shares of AMAG with a target price of $62.
Bear of the Day Palm, Inc. (PALM) - Although 4Q09 revenue declined by 70.7% y-o-y and the loss increased y-o-y, results for Palm, Inc.'s (PALM) quarter were better than expected due to the ramp up in Treo Pro shipments and strong domestic and international carrier interest in its Web OS platform.
Although Palm has had some initial success with the Pre, its next-gen phone, we have doubts on its success as it competes with several much larger competitors such as BlackBerry and iPhone. As the Palm Pre was launched in June, we expect that its impact will be better reflected in the first quarter of fiscal 2010.
Palm has struggled to match supply with demand for the new handset. We have a low confidence on long-term prospects, so we reiterate our Sell rating on Palm but raise our six-month price target to $8.00.
Analyst Interviews Business Consulting Services With Sean P. Smith With businesses in nearly every industry looking for ways to lower non-critical expenses, we expect the business consulting industry to face a challenging operating environment in the near term. We retain Sells on EXBD, NCI and CRAI.
Zacks Industry Rank Analysis Tech - Demand for Hardware Improving By Charles Rotblut New guidance from STX and STEC and better-than-expected results from RIMM and PALM suggests demand for hardware is improving.
View All Company Reports
Performance information for other Zacks’ portfolios and strategies is available at: http://www.zacks.com/performance